Cancer incidence in patients with hereditary hemorrhagic telangiectasia.

about

20-year follow-up study of Danish HHT patients-survival and causes of death Endoglin-based biological therapy in the treatment of angiogenesis-dependent pathologies.Cancer and hereditary haemorrhagic telangiectasia.

P2860

Q37431600-EEB15CAA-2610-4DF7-81EC-305477DF95AB Q39401943-32FDE3C3-93BB-49C7-B562-C764BB2092AC Q46597333-894BAE58-2BB9-4DD1-A305-2A2C7DA34878

P2860

Cancer incidence in patients with hereditary hemorrhagic telangiectasia.

Item

http://www.wikidata.org/entity/Q40577523

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Cancer incidence in patients with hereditary hemorrhagic telangiectasia.

@en

type

Item

label

Cancer incidence in patients with hereditary hemorrhagic telangiectasia.

@en

prefLabel

Cancer incidence in patients with hereditary hemorrhagic telangiectasia.

@en

P1476

Cancer incidence in patients with hereditary hemorrhagic telangiectasia.

@en

P2093

Adam W Black

http://www.w3.org/2001/XMLSchema#string

Calvin P H Vary

http://www.w3.org/2001/XMLSchema#string

Christine W Duarte

http://www.w3.org/2001/XMLSchema#string

F Lee Lucas

http://www.w3.org/2001/XMLSchema#string

P2860

Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1

Cascade effects of medical technology

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Stromal fibroblasts in cancer initiation and progression

Endoglin-mediated suppression of prostate cancer invasion is regulated by activin and bone morphogenetic protein type II receptors.

Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome).

Endoglin suppresses human prostate cancer metastasis.

Metabolic syndrome and risk of endometrial cancer in the united states: a study in the SEER-medicare linked database

Endoglin regulates cancer-stromal cell interactions in prostate tumors

A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.

P2888

s00432-016-2272-7

P304

209-214

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00432-016-2272-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

143

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27638773

http://www.w3.org/2001/XMLSchema#string

P921

hereditary hemorrhagic telangiectasia

P932

5263109

http://www.w3.org/2001/XMLSchema#string

Cancer incidence in patients with hereditary hemorrhagic telangiectasia.

about

P2860

P2860

Cancer incidence in patients with hereditary hemorrhagic telangiectasia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P932